Evidence map›Paper›PMID 26124688›Full record

ReviewJournal of blood medicine2015

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.

Antoine N Saliba, Afif R Harb, Ali T Taher

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of blood medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Iron chelators: as therapeutic agents in diseases.Annals of medicine and surgery (2012) · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Antoine N SalibaDepartment of Internal Medicine, Division of Hematology/Oncology, American University of Beirut, Beirut, Lebanon.
Afif R HarbDepartment of Internal Medicine, Division of Hematology/Oncology, American University of Beirut, Beirut, Lebanon.
Ali T TaherDepartment of Internal Medicine, Division of Hematology/Oncology, American University of Beirut, Beirut, Lebanon.
American University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transfusional iron overload is a major target in the care of patients with transfusion-dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver, heart, and endocrine organs leading to a wide array of complications. In this review, we summarize the characteristics of the approved iron chelators, deferoxamine, deferiprone, and deferasirox, and the evidence behind the use of each, as monotherapy or as part of combination therapy. We also review the different guidelines on iron chelation in TDT. This review also discusses future prospects and directions in the treatment of transfusional iron overload in TDT whether through innovation in chelation or other therapies, such as novel agents that improve transfusion dependence.

Indexed as

iron chelation therapyiron overloadthalassemiatransfusiontransfusion-dependent thalassemia

Identifiers

PMID26124688
PMCPMC4476479
OpenAlexW2109853368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.